Publication | Open Access

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Hematological MalignancyLymphoid NeoplasiaOncologyMantle Cell LymphomaSystemic TreatmentHematologyFrontline TreatmentPhase 2ImmunotherapyMedicineRadiation OncologyHealth Sciences